HER2阳性乳腺癌靶向治疗药物的临床研究进展  

Clinical research progress of targeted therapy for HER2-positive breast cancer

作　　者：何馨彤 王上 张紫筝 赵凌霄 曲连悦[1] 林建阳[1] HE Xintong;WANG Shang;ZHANG Zizheng;ZHAO Lingxiao;QU Lianyue;LIN Jianyang(Department of Pharmacy,the First Affiliated Hospital of China Medical University,Shenyang 110001,China;College of Pharmaceutical Science,China Medical University,Shenyang 110122,China;Dalian Medical University,Dalian 116000,China)

机构地区：[1]中国医科大学附属第一医院药学部,辽宁沈阳110001 [2]中国医科大学药学院,辽宁沈阳110122 [3]大连医科大学,辽宁大连116000

出　　处：《药物评价研究》2021年第12期2697-2704,共8页Drug Evaluation Research

基　　金：国家自然基金青年科学基金资助项目(81302841);辽宁省高等学校优秀人才支持计划资助项目(LJQ2014086)。

摘　　要：乳腺癌已成为全球最常见的癌症,人表皮生长因子受体2(HER2)阳性乳腺癌恶性程度较高,早期易复发和转移,总体预后较差。HER2阳性乳腺癌的治疗因靶向药物的不断问世而呈现更多可能,这类药物包括单克隆抗体(曲妥珠单抗、帕妥珠单抗)、酪氨酸激酶抑制剂(奈拉替尼、拉帕替尼、吡咯替尼、图卡替尼)、抗体药物偶联物(T-DM1、DS-8201)。对HER2阳性乳腺癌靶向治疗药物的最新临床试验结果进行综述,以期为该类乳腺癌的临床用药提供参考。Breast cancer has become the most common cancer in the world. Among them, human epidermal growth factor receptor 2(HER2)-positive breast cancer is highly malignant, easy to relapse and metastasize in the early stage and the overall prognosis is poor. With the advent of targeted drugs, more possibilities have been provided for the treatment of HER2-positive breast cancer.These drugs include monoclonal antibodies(trastuzumab, pertuzumab), tyrosine kinase inhibitors(neratinib, lapatinib, pyrotinib and tucatinib), antibody drug conjugates(T-DM1, DS-8201). This article aims to review the latest clinical trial results of targeted therapy drugs for HER2-positive breast cancer, in order to provide a reference for future clinical medication.

关 键 词：乳腺癌 人表皮生长因子受体2 靶向治疗 单克隆抗体 酪氨酸激酶抑制剂 抗体药物偶联物 

分 类 号：R979.1[医药卫生—药品] R984[医药卫生—药学]